Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Spine Wave raises $45 million: Spinal implant developer Spine Wave raises $45 million in a private placement to support expansion of its U.S. sales force and global distribution network, as well as R&D efforts and clinical trials, the firm says. Shelton, Conn.-based Spine Wave's U.S. offerings include the StaXx XD expandable polyetheretherketone (PEEK) spacer for vertebral body replacement and the CapSure PS top loading pedicle screw system for treating degeneration, tumor, or trauma of the thoracolumbar spine. Outside the United States the firm also offers the StaXx FX minimally invasive system for repairing vertebral compression fractures, and the NuCore injectable nucleus for early-stage degenerative disc disease. Founded in 2001 by former execs of spinal device powerhouse Sofamor Danek, privately held Spine Wave's latest financing round was led by Compass Global Fund...

You may also be interested in...

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

Sabinsa Reaches Out To US Regulators To Squeeze Fake Vitamin C Out Of Ingredient Markets

Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts